Shanghai Medicilon Inc.

  Shanghai, China/San Diego,USA - August 2, 2023, ABM Therapeutics announced that its self-developed small molecule BRAF inhibitor ABM-1310 has obtained orphan drug qualification from the US FDA for the treatment of BRAF V600 mutant brain glioblastoma (GBM). In the research and development of ABM-1310, the  chemical FTE (Full-time equivalent)  team of Shanghai Medicilon Inc provided  drug discovery services  in a flexible cooperation mode.  It has laid a solid foundation for ABM Therapeutics' ABM-1310 to obtain the US FDA Orphan Drug Qualification. Medicilon Chemical FTE Team Facilitate Rapid Discovery of Innovative Drugs The chemical FTE team of Medicilon can serve clients in different stages of drug development, including the generation and optimization of hit compounds, the identification and optimization of lead compounds, synthesis amplification chemical process research and other services.  This collaboration model is based on client and project needs, and can flexibly adjust

  GLP-1 New Drug R&D Service: Introduction of GLP-1s Glucagon-like peptide-1 (GLP-1) is a 30- or 31-amino-acid-long peptide hormone. GLP-1 exists in two equally bioactive forms, GLP-1 (7-37) amide and GLP-1 (7-36) amide. GLP-1 is a biological product derived from the post-translational processing of proglucagon. GLP-1 is secreted by the enteroendocrine L cells, but also by some neuronal populations in the hindbrain. GLP-1 potentiates insulin release and reduces glucagon’s concentration in physiological conditions. GLP-1 New Drug R&D Service GLP-1 New Drug R&D Service Medicilon provides GLP-1 drug discovery, CMC research (API + formulation), pharmacodynamics research, PK study, GLP-1 safety evaluation and other services. As of the end of May 2023, Medicilon has successfully assisted in the clinical approval of 7 GLP-1 drugs (3 approved by FDA and NMPA，1 approved by FDA, NMPA, and TGA) and has multiple GLP-1 projects under development.

Medicilon Botanical Drug Preclinical R&D Technology Service Platform is established based on the existing drug pharmacokinetic and safety evaluation research platform of the company with over decade of research and development experience. Medicilon Botanical Drug Preclinical R&D Technology Service Platform is established based on the existing drug pharmacokinetic and safety evaluation research platform of the company with over decade of research and development experience. It is dedicated to providing customized preclinical trial service solutions for clients, with a professional technical service team specializing in drug metabolism, pharmacokinetics, efficacy research, and toxicology. Meanwhile，Shanghai Medicilon Inc. (referred to as Medicilon) can assist clients to overcome the bottlenecks in botanical drug development. Medicilon provides high-quality data and rapid turnover to support various drug development and preclinical research activities, in order to help clients se

  Caco-2 cells are human colon cancer cell line commonly used to simulate the characteristics and functions of the epithelial cell layer of the human small intestine. This cell line was first isolated from a tumor in a male patient with colon adenocarcinoma in 1977 and was named Caco-2. Caco-2 Permeability Assay is a commonly used in vitro experimental method to evaluate the absorption and permeability of compounds in the human intestinal tract. The absorption and permeability of drugs are important pharmacokinetic parameters when administered orally. Based on the characteristics of the human colon cancer cell line Caco-2, it is possible to predict the oral bioavailability of compounds by simulating the conditions of the small intestinal epithelial cell layer. When Caco-2 cells are cultured on permeable polycarbonate membranes, they form a monolayer of epithelial cells that can simulate the morphology of human intestinal epithelial cells, with apical (AP) and basolateral (BL) structure

  On August 7, 2023, the Shanghai Stock Exchange officially launched the SSE Science and Technology Innovation Board 100 Index, a new index added to the STAR Market.  The SSE Science and Technology Innovation Board 100 Index selects 100 stocks with medium market capitalization and good liquidity from the STAR Market as index samples, and together with the SSE Science and Technology Innovation Board 50 Index to constitute the SSE Science and Technology Innovation Board Scale Index Series.  Shanghai Medicilon Inc. ( Medicilon , stock code "688202.SH") was selected as one of the SSE Science and Technology Innovation Board 100 Index. The SSE Science and Technology Innovation Board 100 Index has distinct characteristics. Taking the latest sample as an example, the Chinese pharmaceutical industry accounts for nearly 30% of the SSE Science and Technology Innovation Board 100 Index.  In terms of innovation capability and performance growth, the total investment in research and develo

  In 1893, William Coley, a New York orthopedic surgeon, accidentally discovered that postoperative streptococcus pyogenes infection caused tumor regression in patients with sarcoma, which opened the prelude to immunotherapy.  After countless explorations, although immunotherapy has added milestones one after another to the history of human anti-cancer, this marathon is far from reaching the end.  In 2018, under the era of great changes in the China medical system and investment environment, Dr. Xin Dong believes that immunotherapy will set off a new revolution and bring infinite possibilities to life.  Dr. Dong founded Neologics Bioscience (Neologics) and committed to the development of "global new" R&D pipelines for the immune regulation mechanism of anti-tumor and inflammation based on innovation.  In May of this year, the IND application for NB002, the first new drug of Neologics, was approved by the FDA for clinical approval, successfully taking a key step towards in

  On July 25, 2023, Fosun Health Capital established by Fosun Pharma（stock code:600196.SH), reached a strategic partnership with Medicilon（stock code: 688202.SH). Meanwhile StarMab Biology (Suzhou) ( referred to as "StarMab Biology"，jointly invested by the innovation drug research fund of Fosun Group and Yaopharma) and Medicilon entered into a strategic cooperation for innovative drug IND research and application services. This strategic partnership indicates a significant step forward in the cooperation between Fosun Health Capital and Medicilon, with milestone for both parties' development. Cui Zhiping, Co-CEO and General Manager of Fosun Health Capital, Chen Chunlin, Founder and CEO of Medicilon, along with members from both sides attended the signing ceremony together and witnessed the contract. According to the strategic cooperation agreement, Medicilon will leverage its international perspective and rich experience in R&D to provide innovative drug enterprises i